195 related articles for article (PubMed ID: 37453852)
21. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
[TBL] [Abstract][Full Text] [Related]
23. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
[TBL] [Abstract][Full Text] [Related]
24. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review.
Yassen M; Changal K; Busken J; Royfman R; Schodowski E; Venkataramany B; Khouri SJ; Moukarbel GV
Am J Cardiol; 2024 Jan; 210():219-224. PubMed ID: 37884110
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
Dong T; Nissen S; Ospina S; Desai MY
Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
[TBL] [Abstract][Full Text] [Related]
27. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
Chase Cole J; Benvie SF; DeLosSantos M
Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis.
Memon A; Larik MO; Khan Z; Urooj M; Irfan A; Kumari B; Faisal M; Siddiqui R; Tehrim M; Hameed I
Future Sci OA; 2023 Dec; 9(10):FSO898. PubMed ID: 37753355
[TBL] [Abstract][Full Text] [Related]
29. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
[TBL] [Abstract][Full Text] [Related]
30. [Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment].
Lancellotti P; de Marneffe N; Scheen A
Rev Med Liege; 2024 Feb; 79(2):120-128. PubMed ID: 38356430
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials.
Rabiee Rad M; Ghasempour Dabaghi G; Habibi D
Egypt Heart J; 2023 Jan; 75(1):4. PubMed ID: 36633717
[TBL] [Abstract][Full Text] [Related]
32. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.
Tower-Rader A; Ramchand J; Nissen SE; Desai MY
Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741
[TBL] [Abstract][Full Text] [Related]
33. Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
Bertero E; Chiti C; Schiavo MA; Tini G; Costa P; Todiere G; Mabritto B; Dei LL; Giannattasio A; Mariani D; Lofiego C; Santolamazza C; Monda E; Quarta G; Barbisan D; Mandoli GE; Mapelli M; Sguazzotti M; Negri F; De Vecchi S; Ciabatti M; Tomasoni D; Mazzanti A; Marzo F; de Gregorio C; Raineri C; Vianello PF; Marchi A; Biagioni G; Insinna E; Parisi V; Ditaranto R; Barison A; Giammarresi A; De Ferrari GM; Priori S; Metra M; Pieroni M; Patti G; Imazio M; Perugini E; Agostoni P; Cameli M; Merlo M; Sinagra G; Senni M; Limongelli G; Ammirati E; Vagnarelli F; Crotti L; Badano L; Calore C; Gabrielli D; Re F; Musumeci G; Emdin M; Barbato E; Musumeci B; Autore C; Biagini E; Porto I; Olivotto I; Canepa M
Eur J Heart Fail; 2024 Jan; 26(1):59-64. PubMed ID: 38131253
[TBL] [Abstract][Full Text] [Related]
34. Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center.
Desai MY; Hajj-Ali A; Rutkowski K; Ospina S; Gaballa A; Emery M; Asher C; Xu B; Thamilarasan M; Popovic ZB
Prog Cardiovasc Dis; 2024 Feb; ():. PubMed ID: 38354765
[TBL] [Abstract][Full Text] [Related]
35. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
[TBL] [Abstract][Full Text] [Related]
36. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
[TBL] [Abstract][Full Text] [Related]
37. Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study.
Monda E; Lioncino M; Palmiero G; Franco F; Rubino M; Cirillo A; Verrillo F; Fusco A; Caiazza M; Mazzella M; Moscarella E; Dongiglio F; Sepe J; Pacileo G; Calabrò P; Limongelli G
Int J Cardiol; 2022 May; 354():22-28. PubMed ID: 35278578
[TBL] [Abstract][Full Text] [Related]
38. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Maron MS; Masri A; Nassif ME; Barriales-Villa R; Arad M; Cardim N; Choudhury L; Claggett B; Coats CJ; Düngen HD; Garcia-Pavia P; Hagège AA; Januzzi JL; Lee MMY; Lewis GD; Ma CS; Michels M; Olivotto I; Oreziak A; Owens AT; Spertus JA; Solomon SD; Tfelt-Hansen J; van Sinttruije M; Veselka J; Watkins H; Jacoby DL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Abraham TP;
N Engl J Med; 2024 May; 390(20):1849-1861. PubMed ID: 38739079
[TBL] [Abstract][Full Text] [Related]
39. Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis.
Rangwala HS; Fatima H; Ali M; Ahmed ST; Rangwala BS; Abbas SR
Egypt Heart J; 2023 Dec; 75(1):99. PubMed ID: 38041770
[TBL] [Abstract][Full Text] [Related]
40. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
Wheeler MT; Olivotto I; Elliott PM; Saberi S; Owens AT; Maurer MS; Masri A; Sehnert AJ; Edelberg JM; Chen YM; Florea V; Malhotra R; Wang A; Oreziak A; Myers J
JAMA Cardiol; 2023 Mar; 8(3):240-247. PubMed ID: 36652223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
